BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study
Tóm tắt
Male breast cancer (MBC) is a rare disease that represents <1 % of all breast cancers (BCs). We analyze the results of a multicenter study performed in Spanish familial MBC including family history of hereditary breast and ovarian cancer syndrome (HBOCS) and clinicopathological features. We also study the relationship between BRCA1/BRCA2 mutational status in male relatives affected with cancer (MAC) and, family history and tumor types. The study included 312 men index cases with family history of HBOCS and 61 MAC BRCA1/2 mutation-carriers. Family history, histological grade (HG), clinicopathological and immunohistochemistry data were collected. BRCA1/2 mutation analyses were performed by direct sequencing or screening methods and the large rearrangements by multiplex ligation dependent probe amplification. We found 49 mutation-carriers (15.7 %), 95.9 % with BRCA2 mutations. BRCA2 mutation-carriers were associated with families with at least one MBC and one BC in female (type II; p = 0.05). Strong association were found between the presence of pathogenic mutations in MBCs and the advanced HG (p = 0.003). c.658_659delTG, c.2808_2811delACAA, c.6275_6276delTT and c.9026_9030delATCAT were the most prevalent mutations. In 61 MAC we found 20 mutations in BRCA1 and 41 in BRCA2. For MAC we show that mutational status was differentially associated with family history (p = 0.018) and tumor type, being BRCA2 mutations linked with BC and prostatic cancer (p = 0.018). MBC caused by BRCA1/2 mutations define two types of MBCs. The most frequent caused by BRCA2 mutation linked to type II families and the rarest one attributed to BRCA1 mutation. Tumor associated with MAC suggest that only BRCA2 mutations have to do with a specific type of cancer (BC and prostatic cancer); but the linkage to tumors is questionable for BRCA1 mutations
.
Tài liệu tham khảo
Korde Larissa A, Zujewski Jo Anne, Kamin Leah et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114–2122
Couch FJ, Farid LM, DeShano ML et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13:123–125
Haraldsson K, Loman N, Zhang QX et al (1998) BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58:1367–1371
Thorlacius S, Tryggvadottir L, Olafsdottir GH et al (1995) Linkage to BRCA2 region in hereditary male breast cancer. Lancet 346:544–545
Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792
Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372
Anelli A, Anelli TF, Youngson B et al (1995) Mutations of the p53 gene in male breast cancer. Cancer 75:2233–2238
Fackenthal JD, Marsh DJ, Richardson AL et al (2001) Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 38:159–164
Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59
Cancer risks in (1999) BRCA2 mutation carriers: the Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310–1316
Edwards SM, Kote-Jarai Z, Meitz J et al (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1–12
Ottini L, Silvestri V, Rizzolo P et al (2012) Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat 134:411–418
World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects [http://www.wma.net/e/policy/pdf/17c.pdf]
Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 90:10325–10329
Velasco E, Infante M, Durán M et al (2007) Heteroduplex analysis by capillary array electrophoresis for rapid mutation detection in large multiex genes. Nat Protoc 2(1):237–246
Mattocks CJ, Watkins G, Ward D et al (2010) Interlaboratory diagnostic validation of conformation-sensitive capillary electrophoresis for mutation scanning. Clin Chem 56(4):593–602
van der Stoep N, van Paridon CD, Janssens T, Krenkova P, Stambergova A, Macek M, Matthijs G, Bakker E (2009) Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner. Hum Mutat 30(6):899–909. doi:10.1002/humu.21004
de Juan I, Esteban E, Palanca S, Barragan E, Bolufer P (2009) High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations. Breast Cancer Res Treat 115:405–414
Schouten JP et al (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12):e57
Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(7):e48–e72
Milanezi F, Carvalho S, Schmitt FC (2008) EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 8(4):417–434
Ding YC, Steele L, Kuan C-J, Greilac S, Neuhausen SL (2011) Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. 126(3):771–778. doi:10.1007/s10549-010-1195-2
Hereditary Breast and/or ovarian syndrome. National Comprenhensive Cancer Network NCCN Guidelines Version 1.2014.HBOC-1
Deb S, Jene N, kConFab investigators, Fox SB (2012) Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer 12:510. doi:10.1186/1471-2407-12-510
Loughrey M, Provan PJ, Byth K, Balleine RL (2008) Histopathological features of ‘BRCAX’ familial breast cancers in the kConFab resource. Pathology 40(4):352–358
Díez O, Osorio A, Durán M et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22(4):301–312
Esteban Cardeñosa E, Bolufer Gilabert P, de Juan Jimenez I et al (2010) Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population. Breast Cancer Res Treat 121:257–260
Diez O, Gutiérrez-Enríquez S, Balmaña J (2010) Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. Fam Cancer 9:187–191
de Juan Jiménez I, García Casado Z, Palanca Suela S et al (2013) Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Fam Cancer 12(4):767–777
Breast Cancer Information Core: BIC: [http://research.nhgri.nih.gov/bic/]
The Universal Mutation Database: UMD: [http://www.umd.be/]
Neuhausen SL, Godwin AK, Gershoni-Baruch R et al (1998) Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 62:1381–1388
Llort G, Yagüe C, Peris M et al (2002) Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. Hum Mutat 19:307
Gutierrez-Enrique S, de la Hoya M, Martínez-Bouzas C et al (2007) Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat 103:103–107
Menéndez M, Castellsagué J, Mirete M et al (2012) Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 132(3):979–992
del Valle J, Feliubadaló L, Nadal M et al (2010) Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 122(3):733–743
The BRCA1 Exon 13 Duplication Screening Group (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 67(1):207–212
Vega A, Torres M, Martínez JI et al (2002) Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian Peninsula. Ann Hum Genet 66:29–36